



Current and Emerging Biological and Oral/Topical Small-Molecule Treatments for Psoriasis

Guest Editor:

Prof. Dr. Tiago Torres

1. Department of Dermatology,
Centro Hospitalar Universitário
do Porto, Porto, Portugal
2. Instituto de Ciências
Biomédicas Abel Salazar,
University of Porto, Porto,
Portugal

Deadline for manuscript
submissions:
closed (31 December 2023)

Message from the Guest Editor

Dear Colleagues,

Psoriasis is a chronic, systemic, immune-mediated disease associated with several comorbidities. Although its pathogenesis is complex and not yet fully understood, the interleukin (IL)-23/IL-17 axis is currently thought to be its main pathogenic pathway. The knowledge acquired over the last decade regarding psoriasis's pathogenesis has led to the development of new targeted therapeutic options including biologic agents and small molecules (both oral and topical) that enable clinicians to better manage psoriasis patients. Main targets include cytokines related to the IL-23/IL-17 axis and their intracellular signalling pathway (JAK-STAT, PDE4 and others); however, many other agents (topical, oral and parenteral drugs) with different targets are in the pipeline. This Special Issue aims to review recent and future therapy developments for the treatment of psoriasis.

Prof. Dr. Tiago Torres
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of
Pharmacy, Rutgers, The State
University of New Jersey, William
Levine Hall, Room 225C, 160
Frelinghuysen Road, Piscataway,
NJ 08854-8020, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceutics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma